| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/20/2009 | EP2059530A1 Method for the production of insulin-like growth factor-i |
| 05/20/2009 | EP2059527A2 Modified proteins |
| 05/20/2009 | EP2059523A2 High pressure treatment of proteins for reduced immunogenicity |
| 05/20/2009 | EP2059260A2 Pharmaceutical compositions comprising hgh for oral delivery |
| 05/20/2009 | EP2059254A1 Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
| 05/20/2009 | EP2059253A2 Modulation of regulatory t cells by human il-18 |
| 05/20/2009 | EP2059236A2 Combination with bis(thiohydrazide amides) for treating cancer |
| 05/20/2009 | EP2059233A2 Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses therof |
| 05/20/2009 | EP1978994A4 Bmp-7 variant compositions, methods and uses |
| 05/20/2009 | EP1870106B1 Combination of egf/ghrp-6 for neuroregeneration of central nervous system |
| 05/20/2009 | EP1773348A4 Tetrapeptide analogs |
| 05/20/2009 | EP1656458B1 Human autism susceptibility gene and uses thereof |
| 05/20/2009 | EP1562620B1 Modified cytokines for use in cancer therapy |
| 05/20/2009 | DE102007054877A1 Use of hyaluronidase e.g. as a drug for the treatment of profibrotic metabolic disorder, fibrotic liver disease, chronic viral liver disease, portal hypertension, chronic hepatitis C and hepatocellular carcinoma |
| 05/20/2009 | CN101437849A Insulin derivative |
| 05/20/2009 | CN101437848A Selective VPAC2 receptor peptide agonists |
| 05/20/2009 | CN101437543A Combination comprising a VEGF inhibitor and a serine protease for treating neovascular diseases |
| 05/20/2009 | CN101437542A Cancer treatment combining lymphodepleting agent with CTLs and cytokines |
| 05/20/2009 | CN101437540A Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| 05/20/2009 | CN101437535A Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection |
| 05/20/2009 | CN101437534A Broad spectrum immune and antiviral gene modulation by oral interferon |
| 05/20/2009 | CN101437533A Antisecretory protein for use in the treatment of compartment syndrome |
| 05/20/2009 | CN101437532A Phage derived antimicrobial activities |
| 05/20/2009 | CN101437531A Compositions of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer |
| 05/20/2009 | CN101437501A Prolongation of survival of an allograft by inhibiting complement activity |
| 05/20/2009 | CN101434964A Cholera toxin B subunit and lumbrokinase fusion gene, as well as recombinant vector and host cell including the same |
| 05/20/2009 | CN101434962A Japanese blood fluke (Chinese mainland strain) tyrosine kinase TK4 conserved region gene, and cloning expression method and use thereof |
| 05/20/2009 | CN101434955A Recombinant expression method of insect C-type lectin and use |
| 05/20/2009 | CN101434942A Novel method for extracting and purifying beer malt root phospholipase D |
| 05/20/2009 | CN101434657A Preparation and use of recombinant mtVEGF121/MAP30KDEL fusion noxioussubstance |
| 05/20/2009 | CN101434656A Preparation and use of OPG-HSP70 fusion protein |
| 05/20/2009 | CN101434650A Bursa pentapeptide, deriving peptide thereof and use thereof |
| 05/20/2009 | CN101434649A Small peptide, preparation thereof and use thereof in diagnosis or treatment of PACAP and VIP related diseases |
| 05/20/2009 | CN101434648A Peptide for inhibiting angiogenesis, and use thereof in angiogenesis medicament preparation |
| 05/20/2009 | CN101434647A Epitope/peptide recognized by hla-a2402-restricted ep/cam-specific ctl and use of the same |
| 05/20/2009 | CN101433722A Fusions of cytokines and tumor targeting proteins |
| 05/20/2009 | CN101433718A Biodegradable polypeptide vesicle loaded with hemoglobin and preparation method thereof |
| 05/20/2009 | CN101433715A Modified chimeric polypeptides with improved pharmacokinetic properties |
| 05/20/2009 | CN101433714A Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation |
| 05/20/2009 | CN101433713A GnRH-PE mutant fusion protein and uses thereof |
| 05/20/2009 | CN101433712A Liver perfusate and preparation method thereof |
| 05/20/2009 | CN101433625A Compound trepang glycopeptide oral liquid |
| 05/20/2009 | CN101433515A High-efficient low-toxicity ultrasonic microvesicle for carrying ricin A chain and preparation method thereof |
| 05/20/2009 | CN101433513A Semi-interpenetrating network polymer gel for oral colon-specific drug release system and preparation method thereof |
| 05/20/2009 | CN100489098C Goose B lymphocyte stimulating factor CDNA, and its cloning method and recombinant use |
| 05/20/2009 | CN100489094C Proteins with altered immunogenicity and methods of making and using the same |
| 05/20/2009 | CN100489093C Protein and nuclear acid of antrodia camphoratu antioxidase and preparation method and use thereof |
| 05/20/2009 | CN100488984C Reducing immunogenicity of fusion proteins |
| 05/20/2009 | CN100488981C Proaerolysin containing protease activation sequences and its uses |
| 05/20/2009 | CN100488980C Integrin binding motif containing peptides and its uses |
| 05/20/2009 | CN100488566C Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant |
| 05/20/2009 | CN100488563C Modified anti-EGFR antibody with reduced immunogenicity |
| 05/20/2009 | CN100488562C Clotting factor VII or VIIa like molecules |
| 05/20/2009 | CN100488561C Method for preparing interferon long-acting injection microsphere preparation |
| 05/20/2009 | CN100488560C Method for preparing mass micro-capsule |
| 05/20/2009 | CN100488512C Compositions for treatment of cell proliferative disorders and its uses |
| 05/20/2009 | CN100488502C Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| 05/20/2009 | CN100488501C Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyper-permeability or undesired permeability |
| 05/20/2009 | CN100488471C Nano antibiotic antiviral condom |
| 05/19/2009 | US7534879 2'-O-methyl-phosphorothioate oligoribonucleotide modification; peptide nucleic acids, locked nucleic acids, and/or morpholino phosphorodiamidate oligonucleotides; splicing |
| 05/19/2009 | US7534870 Stable pharmaceutical composition comprising erythropoietin |
| 05/19/2009 | US7534869 Small and intermediate conductance, calcium-activated potassium channels and uses thereof |
| 05/19/2009 | US7534867 proteins and mimetics which regulate development, differentiation, and function of various cell types, including hematopoietic cells |
| 05/19/2009 | US7534863 Leucine-based motifs and enhanced biological persistence of clostridial neurotoxins |
| 05/19/2009 | US7534862 Polypeptide-dimers for use in treatment and prevention of infection, bone, blood, eating, tumor, autoimmune and inflammatory disorders |
| 05/19/2009 | US7534859 Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse |
| 05/19/2009 | US7534858 For therapy of inflammatory disorders; polypeptide comprising a membrane translocation domain and a NF- kappa B Essential Modulator (NEMO) binding sequence |
| 05/19/2009 | US7534857 Methods and compositions for the treatment and prevention of staphylococcal infections |
| 05/19/2009 | US7534819 Compositions and methods for intracellular delivery of biotinylated cargo |
| 05/19/2009 | US7534776 Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 05/19/2009 | US7534774 Contacting a wound site with formulation comprising nucleic acid molecule and a biocompatible matrix, the wound site being situated in a tissue associated with the fluid space |
| 05/19/2009 | US7534773 reduces the expression of testosterone-repressed prostate message-2 provides therapeutic benefits in the treatment of cancer for example prostate cancer and renal cell cancer; Combined use with taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer |
| 05/19/2009 | US7534765 Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin |
| 05/19/2009 | US7534764 Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin |
| 05/19/2009 | US7534763 Sustained release GLP-1 receptor modulators |
| 05/19/2009 | US7534761 Charged peptide-amphiphile solutions and self-assembled peptide nanofiber networks formed therefrom |
| 05/19/2009 | US7534613 Methods of treating parkinson's disease using viral vectors |
| 05/19/2009 | US7534603 Fusion protein delivery system and uses thereof |
| 05/19/2009 | US7534595 variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type; treating an infant having phenylketonuria; treating pregnant woman with hyperphenylalaninemia |
| 05/19/2009 | US7534593 Crystals of glucokinase and methods of growing them |
| 05/19/2009 | US7534585 Multifunctional cytokines |
| 05/19/2009 | US7534575 Method for detecting cancer using an antibody to Zcytor16 |
| 05/19/2009 | US7534573 comprising transfecting said neurons with a nucleic acid encoding a protein that is targeted to synaptic vesicles and that fluoresces when synaptic vesicles undergo exocytosis; for use in treating epilepsy and other brain disorders |
| 05/19/2009 | US7534572 Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue |
| 05/19/2009 | US7534564 Methods and compositions for polypeptide engineering |
| 05/19/2009 | US7534450 Promoting metallothioneins by administering a copper-free nutrient supplement containing 50 - 150 mg of zinc, and further containing vitamin B6, pyridoxal-5'-phosphate, vitamin E, vitamin A, vitamin C, selenium, glutathione, taurine, and a mixture of amino acids |
| 05/19/2009 | US7534445 isolated nucleotide sequences and degenerate sequences encoding the high molecular weight HMW protein; vaccines; antibodies; vectors |
| 05/19/2009 | US7534444 Molecular mimetics of meningococcal B epitopes which elicit functionally active antibodies |
| 05/19/2009 | US7534441 Immunogenic LHRH compositions and methods relating thereto |
| 05/19/2009 | US7534440 Fusion molecules and methods for treatment of immune diseases |
| 05/19/2009 | US7534439 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses |
| 05/19/2009 | US7534438 Reducing viscosity, cohesion; mixture containing thioreodxin; cystic fibrosis |
| 05/19/2009 | US7534437 new mutant forms of the Sm14 protein, for producing a greater production volume; providing protection against schistosome and fasciola infection |
| 05/19/2009 | US7534436 Peptide fragments of the harp factor inhibiting angiogenesis |
| 05/19/2009 | US7534431 Targetting antibodies containing haptens, cleaning agent, and drug delivery agent; tissue-directed therapy; solid phase synthesis |
| 05/19/2009 | US7534430 Administering monoclonal or polyclonal antibody to treat multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease |
| 05/19/2009 | US7534428 Antibodies to tumor necrosis factor receptors 6α and 6β |
| 05/19/2009 | US7534427 Predosing with non-radiolabeled antibody not performed |
| 05/19/2009 | US7534426 Glutenase enzyme assays |
| 05/19/2009 | US7534423 administering to said individual an effective amount of either i) recombinant protein CD73 or ii) a cytokine or another factor-being capable of inducing endothelial CD73 expression; inflammation |